Clinical Trial Update: CS-121 APOC3 Base Editing in Children and Adolescents With Hyperchylomicronemia [EARLY_Phase 1]

View source ↗

Summary

CS-121 APOC3 base editing for hyperchylomicronemia in children and adolescents is in EARLY Phase 1 and currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Chylomicronemia Syndrome

Drugs mentioned

• CS-121 APOC3 base editing (APOC3 base editing therapy)

Snippet

Sponsor: Shanghai Jiao Tong University School of Medicine | Conditions: Hyperchylomicronemia | EARLY_Phase 1 | Status: RECRUITING